Literature DB >> 9591913

Torsades de Pointes associated with intravenous haloperidol in critically ill patients.

N D Sharma1, H S Rosman, I D Padhi, J E Tisdale.   

Abstract

In this retrospective case-control study, 8 of 223 consecutive patients (3.6%) treated with intravenous haloperidol developed torsades de pointes, and were compared with 41 patients randomly selected as controls. The likelihood of torsades de pointes associated with intravenous haloperidol is significantly greater in patients receiving > or = 35 mg over 24 hours or in those with a QTc interval of >500 ms, or both.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9591913     DOI： 10.1016/s0002-9149(97)00888-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  37 in total

Review 1.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  Pharmacological and nonpharmacological management of delirium in critically ill patients.

Authors:  Dustin M Hipp; E Wesley Ely
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 3.  Delirium and cognitive dysfunction in the intensive care unit.

Authors:  Russell R Miller; E Wesley Ely
Journal:  Curr Psychiatry Rep       Date:  2007-02       Impact factor: 5.285

4.  The use of low-dose IV haloperidol is not associated with QTc prolongation: post hoc analysis of a randomized, placebo-controlled trial.

Authors:  Matthew S Duprey; Nada Al-Qadheeb; Russel Roberts; Yoanna Skrobik; Greg Schumaker; John W Devlin
Journal:  Intensive Care Med       Date:  2016-09-16       Impact factor: 17.440

5.  A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients.

Authors:  Andrew J Muzyk; Sarah K Rivelli; Wei Jiang; Heather Heinz; Amber Rayfield; Jane P Gagliardi
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

6.  Analysis of Orders for QTc-Prolonging Medication for Intensive and Cardiac Care Unit Patients with Pre-existing QTc Prolongation (QTIPPP Study).

Authors:  Vincent H Mabasa; Sayako Yokoyama; Damen Man; John Martyn
Journal:  Can J Hosp Pharm       Date:  2011-11

7.  What causes some patients with drug-induced QT interval prolongation to develop torsades de pointes but not others? The elusive missing link.

Authors:  James E Tisdale
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

Review 8.  Antipsychotic agents and QT changes.

Authors:  R Welch; P Chue
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

9.  Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance.

Authors:  Luigi X Cubeddu
Journal:  Curr Cardiol Rev       Date:  2009-08

Review 10.  Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.

Authors:  Peter M Haddad; Ian M Anderson
Journal:  Drugs       Date:  2002       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.